To the full analysis
Cytek Biosciences stock: growth
CTKBCytek Biosciences reported $201.49M in revenue for fiscal 2025, up 0.5% on the prior year, up 16.8% a year on average over up to five years.
Daily figure as of 12 Nov 2026
Revenue (Annual rate)
23.1%
per year from 2019 to 2025, per share 23.9%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2019 | |
|---|---|---|
| Revenue | 16.8% | 23.1% |
| Revenue per share | 17.7% | 23.9% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2019 | $57.88M | −$16.83M | −$14.72M |
| 2020 | $92.84M | $19.41M | $13.61M |
| 2021 | $127.95M | $3M | $266K |
| 2022 | $164.04M | $2.58M | −$22.1M |
| 2023 | $193.02M | −$12.15M | $454K |
| 2024 | $200.45M | −$6.02M | $21.85M |
| 2025 | $201.49M | −$66.54M | −$8.77M |
Revenue by segment
How Cytek Biosciences, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Product72%
- Service28%
Figures as a table
| 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|
| Product | $119.52M | $148.6M | $156.72M | $153.26M | $144.23M | 71.6% |
| Service | $8.43M | $15.44M | $36.49M | $47.19M | $57.26M | 28.4% |
| Total revenue | $127.95M | $164.04M | $193.02M | $200.45M | $201.49M | 100% |
Revenue by region
Where Cytek Biosciences, Inc. generates its revenue.
- United States47%
- EMEA28%
- Asia Pacific20%
- Other5%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|
| United States | $72.72M | $94.59M | $102.09M | $92.61M | $95.25M | 47.3% |
| EMEA | $36.97M | $43.96M | $53.18M | $62.34M | $55.88M | 27.7% |
| Asia Pacific | $16.08M | $22.52M | $31.6M | $35.77M | $41.08M | 20.4% |
| Other | $2.18M | $2.96M | $6.15M | $9.73M | $9.28M | 4.6% |
| Total revenue | $127.95M | $164.04M | $193.02M | $200.45M | $201.49M | 100% |
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jan 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.